Shattuck Labs, Inc. (STTK) Stock Analysis & Investment Frameworks
Shattuck Labs, Inc. (STTK) stock analysis on Invetso. Review Shattuck Labs, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Shattuck Labs, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Shattuck Labs, Inc. Key Financial Metrics
- Market Cap: $560.03M
- Revenue: $1.00M
- ROE: -43.57%
- ROIC: -26.09%
- Dividend Yield: N/A
About Shattuck Labs, Inc.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.